Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin‐induced type 1 diabetes in rats by Alomari, Ghada et al.
Received: 6 June 2020 - Revised: 17 September 2020 - Accepted: 6 November 2020 - IET NanobiotechnologyDOI: 10.1049/nbt2.12026
OR I G INAL RE SEARCH PA PER
Alleviation of diabetic nephropathy by zinc oxide nanoparticles
in streptozotocin‐induced type 1 diabetes in rats
Ghada Alomari1,2 | Bahaa Al‐Trad2 | Salehhuddin Hamdan1 | Alaa A. A. Aljabali3 |
Mazhar Salim Al Zoubi4 | Khalid Al‐Batanyeh2 | Janti Qar2 | Gregory J. Eaton5 |
Almuthanna K. Alkaraki2 | Walhan Alshaer6 | Saja Haifawi2 | Khairunadwa Jemon1 |
Dinesh Kumar Chellappan7 | Kamal Dua8 | Murtaza M. Tambuwala9
1Department of Bioscience, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru, Johor, Malaysia
2Department of Biological Sciences, Yarmouk University, Irbid, Jordan
3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan
4Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan
5Department of Biological Sciences, College of Science and Mathematics, Rowan University, Glassboro, New Jersey, USA
6University of Jordan, Cell Therapy Center, Amman, Jordan
7Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
8School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, Australia
9School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, UK
Correspondence
Bahaa Al‐Trad, Departments of Biological Sciences,
Yarmouk University, Irbid, Jordan.
Email: bahaa.tr@yu.edu.jo
Ghada Alomari, Departments of Biological Sciences,
Yarmouk University, Irbid, Jordan.
Email: ghada.o@yu.edu.jo
Salehhuddin Hamdan, Department of Bioscience,
Faculty of Science, Universiti Teknologi Malaysia,
81310 Skudai, Johor‐Malaysia.
Email: saleh65@utm.my
Mazhar Salim Al Zoubi, Department of Basic
Medical Sciences, Faculty of Medicine, Yarmouk
University, Irbid 211‐63, Jordan.
mszoubi@yu.edu.jo
Funding information
The Deanship of Scientific Research and Graduate
Studies at the University of Yarmouk, Grant/Award
Number: 34/2017
Abstract
This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic
nephropathy, which is the primary cause of mortality for diabetic patients with end‐stage
renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of
streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7
weeks. Diabetes was associated with increases in blood glucose level, 24‐h urinary al-
bumin excretion rate, glomerular basement membrane thickness, renal oxidative stress
markers, and renal mRNA or protein expression of transforming growth factor‐β1,
fibronectin, collagen‐IV, tumour necrosis factor‐α and vascular endothelial growth factor‐
A. Moreover, the expression of nephrin and podocin, and the mRNA expression of
matrix metalloproteinase‐9 were decreased in the diabetic group. These changes were not
detected in the control group and were significantly prevented by ZnONP treatment.
These results provide evidence that ZnONPs ameliorate the renal damage induced in a
diabetic rat model of nephropathy through improving renal functionality; inhibiting renal
fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the
development of podocyte injury. The present findings may help design the clinical
application of ZnONPs for protection against the development of diabetic nephropathy.
1 | INTRODUCTION
Diabetic nephropathy (DN) is a significant diabetic microvas-
cular complication. The incidence of DN has continued to
increase with the expanding cohort of diabetes patients around
the world [1] and has become a leading cause of chronic kidney
disease in developed countries [2]. Usual DN histological
changes include thickening in both the tubular basement
membrane (TBM) and the glomerular basement membrane
(GBM), mesangial expansion, and afferent and efferent arte-
riolar hyaline deposition [3]. Mesangial enlargement, GBM
thickening, and TBM thickening are consequences of increased
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removal and/or decreased degradation of extracellular matrix
(ECM) proteins such as collagens, laminin, and fibronectin
[3,4]. Moreover, it has been established that podocyte
apoptosis, necrosis or the loss of their adhesive interaction lead
to podocyte detachment from GBM. These cellular pathol-
ogies underlie the progression of DN and cause leakage of
albumin into the urine [3,4].
Under chronic hyperglycemia, many molecular pathways
may affect DN progression. These pathways include ECM
protein deposition, cellular hypertrophy, oxidative stress,
inflammation and apoptosis. Moreover, chronic hyperglyce-
mia enhances flux into the polyol, and hexosamine pathways
increase the formation of advanced glycation end products
and upregulate activation of protein kinase C and trans-
forming growth factor β (TGFβ) signalling pathways [5].
Abnormal angiogenesis also plays a central role in DN
progression [4,6].
The essential trace element zinc (Zn) has different roles
in many biological processes, including as a catalytic
cofactor, in immune response, in the second messenger
system, and in the structural functions of numerous proteins
[7,8]. Systemic Zn deficiency has been associated with a high
incidence of diabetes and advancing DN [9–11]. In addition,
Zn deficiency can cause albuminuria enhancement and ECM
protein expression through the activation of renal interstitial
fibroblasts via the TGF‐β/Smad2/3 pathway, which is
correlated with diabetic renal interstitial fibrosis [12].
Therefore, Zn supplementation has been shown to have
potent anti‐diabetic activity [10], has alleviated the progres-
sion of DN [13], and seems to ameliorate glycaemic control
in type 1 and type 2 diabetes through its insulin‐like effects
and by protecting pancreatic β cells from being destroyed by
immune cells and cytokines [7].
Recently, nanoparticles have been widely used in biomed-
ical applications and have demonstrated several advantages as
therapeutic materials because they can pass through biological
barriers and enhance the bioavailability of therapeutic agents
[14,15]. Recent studies showed that zinc oxide nanoparticles
(ZnONPs) had anti‐hyperglycemic, anti‐oxidative stress, and
anti‐inflammatory effects in a diabetic animal model [16–18].
This study evaluates the possible therapeutic effect of
ZnONPs on DN in a streptozotocin (STZ)‐induced rat model
of type 1 diabetes.
2 | MATERIALS AND METHODS
2.1 | Experimental animals and protocols
The Animal Ethics Committee approved all animal procedures
at Yarmouk University (Irbid, Jordan). Adult male Wistar rats
(weighing 250 g ± 20 g) were kept under specific pathogen‐free
conditions in the Yarmouk University animal housing facility.
After one week of adaptation followed by overnight fasting,
rats were intraperitoneally injected with 55 mg/kg STZ (Chem
Cruz, U‐9889) to induce type I diabetes. Rats received a
drinking water supplemented with sucrose for control of early
death secondary to hypoglycaemic shock (15 g/L) for 48 h.
Three days after STZ injection, rats with a blood glucose level
above 250 mg/dl were considered diabetic [19]. Three different
groups were established randomly: non‐diabetic group (ND,
n = 6), diabetic group without treatment (D, n = 6) and dia-
betic group with daily intraperitoneal injections of 2.5 mg/kg
ZnONPs (D + ZnONPs, n = 6) for 7 weeks. ZnONPs size
<100 nm (TEM) were purchased from Sigma‐Aldrich (Ger-
many, Catalogue No. 721077). The intraperitoneal route of
administration of ZnONPs in the present study was selected
based on a previous study that reported that intraperitoneal
injected ZnONPs were more effectively distributed in the
kidneys than was their distribution following oral administra-
tion [20]. The dose used in this study was selected depending
on different studies that reported non‐toxic, protective, or
recovering roles of ZnONPs on different organs and diseases
[21–25]. In the current study, daily administration of 2.5 mg/kg
ZnONPs in animals was well tolerated for 7 weeks (no sig-
nificant changes in intake of feed, behaviour or mortality rates).
Furthermore, there were no significant effects of hepatic
function analysis from 2.5 mg/kg ZnONPs treatment on
serum alanine aminotransferase and aspartate aminotransferase
levels (Supplement 1).
2.2 | Renal function and biochemical
analysis
After 7 weeks of ZnONPs treatment, rat urine collection was
performed using individual metabolic cages for 24 h. Urinary
albumin concentration was measured using the Albumin Rat
ELISA kit (cat no. ab235642, Abcam, UK) according to
manufacturer instructions. Using commercially available kits,
blood glucose and blood urea nitrogen levels (BUN) were
measured (ARCOMEX, Jordan). The rat kidney weight (mg) to
body weight (g) ratio was calculated to obtain the kidney
weight index (KWI).
2.3 | Assessment of renal oxidative stress
markers
Superoxide dismutase (SOD) (Cayman Chemical, USA),
glutathione peroxidase (GPx) (Cayman Chemical, USA) and
catalase (CAT) (Abbexa Ltd, UK) enzyme activity were
measured in homogenised kidney tissue according to each
kit manufacturer's procedures and recommendations. Renal
tissue malondialdehyde (MDA) level, a lipid peroxidation
marker, was assessed by a method described by Buege and
Aust [26].
2.4 | Renal morphology and
immunohistochemistry
Paraffin sections were prepared and stained with H&E and
periodic acid Schiff (PAS; Sigma‐Aldrich, USA). Prepared
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slides were assessed for any histopathological change under a
light microscope. For ultrastructural evaluation, renal cortical
tissues were fixed in 2.5% glutaraldehyde and postfixed in
sodium cacodylate‐buffered 1% OsO4 (v/v %), dehydrated
and embedded in spur's resin. Ultrathin sections were
processed on an ultratome (Reichert‐Jung Ultratome) and
contrasted using uranyl acetate and lead citrate. Sections were
examined under a Hitachi electron microscope (HT7700‐
Tokyo). The GBM thickness was measured and calculated as
previously detailed [27]. Podocyte number, and foot process
width (FPW) was calculated according to the method of a
previous study [28].
Immunohistochemical staining was performed in 4 µm
paraffin‐embedded sections with specialised detection Kit
(Mouse and Rabbit Specific HRP/DAB IHC–Micropolymer,
Abcam) according to the manufacturer protocol using pri-
mary antibodies against ECM protein collagen IV (1:100;
Abcam/UK; Cat. No. ab6586), the specific podocyte
markers nephrin and podocin (1:100; Abcam/UK; Cat. No.
ab183099 and 1:50; Abcam/UK, Cat. No. ab50339, resp.),
the fibrotic marker TGF‐β1 (1:100; Santa Cruz/USA; Cat.
No. sc‐146) and vascular endothelial growth factor‐A
(VEGF‐A; 1:100; Santa Cruz/USA; Cat. No. sc‐7269).
Negative controls were run by replacing the primary anti-
body with PBS. Under an OPTIKA microscope, section
scoring and analyses were performed with an observer
masked to treatment groups. The mean optical density was
quantified by the use of Fiji ImageJ software in a positively
stained field.
2.5 | Renal morphology and
immunohistochemistry
A cDNA reverse transcription kit (Takara, China) was used
to prepare the cDNA template. Quantitative real‐time RT‐
PCR was conducted using the Line‐Gene 9600 Real‐Time
PCR system (Bioer Technology Co, Binjiang, China) with a
SYBR green PCR master mix (Takara, China). PCR primers
(Table 1) for TGF‐β1, VEGF‐A, MMP‐9, fibronectin, and
TNF‐α were purchased from Integrative DNA Technologies
(Coralville, USA). Amplification conditions were 95°C for
2 min and 45 cycles at 95°C for 30 s and 60°C for 30 s.
The mRNA levels were standardised as a non‐regulated
GAPDH mRNA reference gene. Fold changes in
mRNA expression were determined using the 2−ΔΔCT
method [29].
2.6 | Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 7.00 (GraphPad, San Diego, CA). All results were
expressed as means ± SEM. In the one‐way ANOVA, the
significance of different groups was determined. Significant
differences were tested using an LSD post hoc test for multiple
comparisons (p values < 0.05).
3 | RESULTS
3.1 | Zinc oxide nanoparticle treatment
resulted in decreased blood glucose level and
improved renal function in diabetic
nephropathy
After 7 weeks of STZ administration, diabetic rats showed
significant increases in blood glucose, BUN level, and KWI
compared with the non‐diabetic (ND) group (Figure 1).
Albuminuria is considered a hallmark for the progression of
renal disease, and the increase in the urine urinary albumin
excretion rate (UAE) in addition to the BUN level and KWI
are all indicators for the development of DN in diabetic rats
[30]. ZnONP treatment significantly decreased blood glucose
level and improved renal function in the D + ZnONPs group
(P < 0.05; Figure 1 a–d).
3.2 | Zinc oxide nanoparticle treatment
attenuated renal histopathology injury
As shown in the PAS stain in Figure 2, the diabetic rats showed
GBM thickening and mesangial matrix expansion compared
with ND rats. Electron micrograph studies determined struc-
tural changes in podocyte morphology and GBM thickening.
The ZnONP‐treated diabetic rats exhibited a significant
improvement in ultrastructural abnormalities of the kidney,
such as GBM thickening, loss of podocytes, and podocyte foot
TABLE 1 Sequences of primers used for quantitative real‐time RT‐
PCR
Primer Sequence
GAPDH Left: 50‐ATG GTG AAG GTC GGT GTG‐30
Right: 50‐GAA CTT GCC GTG GGT AGA‐30
VEGF Left: 50‐CGA ACA GAG AGA GGG ACA GG ‐30
Right: 50‐GTC TGT CTG TCT GTC CGT CA ‐30
TGF‐β Left: 50‐CTT CCC CTC CGA AAC TGT CT ‐30
Right: 50‐AGG GTC TGT AGA AAG TGG GC‐30
Collagen IV Left: 50‐ TTG GCT TTC CTG GTA GTC GT ‐30
Right: 50‐ CAA CCT TTC CTG CTT CAC CC ‐30
Fibronectin Left: 50‐ TGA CCG ACG CTA CAG AAA CT ‐30
Right: 50‐ TTG AGC GTG TAC AGG TGG AT ‐30
TNF‐α Left: 50‐ TTC GGA ACT CAC TGG ATC CC ‐30
Right: 50‐ GGA ACA GTC TGG GAA GCT CT ‐30
MMP‐9 Left: 50‐AGG ATG GTC TAC TGG CAC AC ‐30
Right: 50‐GTG CAG GAC AAA TAG GAG CG ‐30
Abbreviations: MMP‐9, matrix metalloproteinase‐9; TNF‐α, transforming growth
factor α; TNF‐β, transforming growth factor β; VEGF, vascular endothelial growth
factor.
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process effacement compared with the D group (P < 0.05;
Figure 3a and b.
3.3 | Zinc oxide nanoparticle treatment
restores the expression of podocyte markers
(nephrin and podocin)
The expression intensity of nephrin and podocin in the
glomeruli were assessed by immunohistochemical staining
(Figure 4a). In the D group, the expression intensity of nephrin
and podocin were significantly decreased compared with the
ND group (Figure 4b, P < 0.05). However, ZnONPs restored
the immunohistochemical staining intensity of both markers in
the ZnONPs + D group.
3.4 | Zinc oxide nanoparticle treatment
reduced renal expression of fibrosis markers in
diabetic nephropathy
To determine the effect of ZnONPs on ECM protein depo-
sition in glomeruli, we analysed the expression of renal
collagen IV and fibronectin, which are the major ECM proteins
that lead to the development of mesangial matrix expansion in
DN [31,32]. Compared with the D group, ZnONP treatment
significantly decreased glomerular collagen IV staining in-
tensity (Figure 5a–b, P < 0.05) and fibronectin mRNA
expression level in the ZnONPs + D group (Figure 5c,
P < 0.05). In addition to increased deposition of ECM,
glucose‐induced inhibition of ECM degrading enzymes such as
MMP‐9 has been shown to contribute to the accumulation of
mesangial ECM proteins in the diabetic kidney [33]. Our re-
sults showed that MMP‐9 mRNA expression was decreased in
the D group compared with the ND group (Figure 5d,
P < 0.05), and ZnONP treatment significantly rescued MMP‐9
mRNA levels in the ZnONPs + D group compared with that
in the D group (P < 0.05).
TGF‐β1 promotes renal cell hypertrophy and stimulates
ECM accumulation, the two hallmarks of DN [34]. As pre-
sented in Figure 6a,b, immunohistochemistry analysis dem-
onstrates that diabetic rats correlated with an overall increase in
the intensity of immunostaining for TGF‐β1. Consistent with
the immunohistochemical findings, the level of TGF‐β1
mRNA was significantly higher in the D group than in the ND
group (Figure 6c; P < 0.05). However, treatment with
ZnONPs resulted in a marked reduction in TGF‐β1 mRNA
and protein expression levels in ZnONPs + D group
compared with the D group.
3.5 | Effect of zinc oxide nanoparticles on
the renal expression of angiogenesis and
inflammatory markers
Inflammation and abnormal angiogenesis play a vital role in
the pathogenesis of diabetes [6,35]. Consistent with the effect
of ZnONPs on TGF‐β1, the mRNA expression of TNF‐α was
also decreased in ZnONP‐treated diabetic rats (Figure 7a,
P < 0.05). The renal VEGF‐A protein and mRNA expression
F I GURE 1 Renal function and biochemical analysis: blood glucose level (a), BUN (b), KWI (c), UAE (d). All values are expressed as mean ± SEM. Symbol
(*) denotes significant differences (P < 0.05) with non‐diabetic, symbol ($) denotes significant differences (P < 0.05) with diabetic group. Abbreviations: ND,
non‐diabetic; D, diabetic; D + ZnONPs, zinc oxide nanoparticle–treated diabetic group; BUN, blood urea nitrogen, KWI, kidney weight/body weight index;
UAE, urine albumin excretion rate
4 - ALOMARI ET AL.
levels in the kidneys from ZnONPs‐treated rats were signifi-
cantly decreased compared with the kidneys of the D group
(Figure 7b–d, P < 0.05).
3.6 | Zinc oxide nanoparticles inhibited the
renal oxidative stress in DN rats induced by
streptozotocin
Compared with the ND rat group, renal tissue MDA level was
remarkably increased (P < 0.05), Figure 8a, while the activities
of SOD (P < 0.05), Figure 8b, CAT (P < 0.05), Figure 8c, and
GPx (P < 0.05), Figure 8d, were significantly reduced in the
diabetic rats. These effects were effectively reversed by
ZnONPs treatment (P < 0.05).
4 | DISCUSSION
In recent years, the use of nanomedicine has increased expo-
nentially, being utilised for diagnosis, prevention and treatment
of different diseases [15]. This study is the first to exclusively
evaluate the possible therapeutic effect of ZnONPs on DN in
an STZ‐induced type 1 diabetes rat model. The STZ‐induced
DN rat model is a well‐characterised model of diabetes mel-
litus–induced renal injury characterised by albuminuria and
F I GURE 2 Representative PAS‐stained cortical renal tissue (magnification �400). Sections from diabetic rats show mesangial expansion and basement
membrane thickening comparing with the ND group, ZnONP treatment attenuated these renal damages. Arrow: mesangial expansion. ND, non‐diabetic; D,
diabetic; ZnONPs + D, zinc oxide nanoparticle–treated diabetic group
F I GURE 3 (a) Representative electron
microscopy images of podocyte foot
processes and the GBM. White arrow: foot
process effacement (magnification �6000);
(b) glomeruli were evaluated to quantify the
GBM thickness, number of podocyte and
FPW. Data are expressed as means ± SEM
(n = 6/each group). Symbol (*) denote
significant differences (P < 0.05) with non‐
diabetic, symbol ($) denotes significant
differences (P < 0.05) with diabetic group.
Abbreviations: GBM, glomerular basement
membrane; FP, foot process; ND: non‐
diabetic; D, diabetic; ZnONPs + D, zinc
oxide nanoparticle–treated diabetic group
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hyperglycemia and associated with mesangial expansion,
thickening of the GBM and loss of podocytes [3].
In DN, changes in GBM thickening and mesangial
expansion are considered the first measurable structural
changes in the glomerulus [3]. These structural changes
cause a decrease in filtration surface area that leads to
reduction in glomerular filtration rate [4]. On the other
hand, albuminuria has been associated with podocyte injury
manifested by foot process widening and effacement,
decreased podocyte number (podocytopenia) and the loss of
slit diaphragm proteins such as nephrin and podocin [4]. In
the current study, ZnONP treatment significantly decreased
GBM thickness and increased podocyte number and the
expression of nephrin and podocin that resulted in
decreased UAE in the diabetic rats. This suggests a potential
protective effect of ZnONPs against albuminuria and
podocyte injury in a rat model of DN. Consistent with our
findings, previous studies have shown that three months of
zinc supplementation in human patients and rats significantly
reduced UAE and prevented diabetes‐induced renal patho-
logical changes and fibrosis [36,37].
Renal fibrosis is mainly intermediated by the pro‐fibrotic
cytokine TGF‐β1 [38]. In addition, excessive ECM protein
accumulation (collagen IV and fibronectin) results from
overproduction or a decrease in ECM protein degradation
by MMPs and is associated with diabetic renal fibrosis [3].
F I GURE 4 (a) Representative nephrin and podocin immunohistochemical staining of the kidney sections (haematoxylin staining; magnification �400).
(b) Quantification of nephrin and podocin immunohistochemistry results expressed as integral optical density of brown staining in the different groups. Data
represent mean ± SEM. Symbol (*) denotes significant differences (P < 0.05) with non‐diabetic, symbol ($) denotes significant differences (P < 0.05) with
diabetic group. Abbreviations: ND, non‐diabetic; D, diabetic; ZnONPs + D, zinc oxide nanoparticle–treated diabetic group; OD, optical density
F I GURE 5 (a) Representative COL‐IV immunohistochemical stain of kidney sections (haematoxylin staining; magnification �400). (b) Quantification of
COL‐IV immunohistochemistry results expressed as integral optical density of brown staining in the different groups. (c) mRNA fibronectin expression level.
(d) mRNA MMP‐9 expression level data represent mean ± SEM. Symbol (*) denotes significant differences (P < 0.05) with non‐diabetic, symbol ($) denotes
significant differences (P < 0.05) with diabetic group. Abbreviations: ND, non‐diabetic; D, diabetic; ZnONPs + D, zinc oxide nanoparticle–treated diabetic
group; OD, optical density; COL‐IV, collagen IV; MMP‐9, matrix metalloproteinase‐9
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Although the exact mechanism of the anti‐fibrotic role of
ZnONPs treatments in DN disease is not well understood
in this study, we demonstrate that ZnONP treatment
decreased the expression of TGF‐β1, collagen IV, and
fibronectin and increased the expression of MMP‐9 in the
diabetic kidney. A decline in the expression and activity of
F I GURE 6 (a) Representative TGF‐β1 immunohistochemical staining of the kidney sections (haematoxylin staining; magnification �400).
(b) Quantification of the immunohistochemistry results expressed as integral optical density of brown staining in the different groups. (c) mRNA TGF‐β1
expression level. Data represent the mean ± SEM. Symbol (*) denotes significant differences (P < 0.05) with non‐diabetic, symbol ($) denotes significant
differences (P < 0.05) with diabetic group. Abbreviations: ND, non‐diabetic; D, diabetic; ZnONPs + D, zinc oxide nanoparticle–treated diabetic group; OD,
optical density; TGF‐β1, transforming growth factor β1
F I GURE 7 (a) Representative VEGF‐A immunohistochemical stain of the kidney sections (haematoxylin staining; magnification �400). (b) Quantification
of the immunohistochemistry results expressed as integral optical density of brown staining in the different groups. (c) mRNA expression level of VEGF‐A.
(d) mRNA TNF‐α expression level. Data represent the mean ± SEM. Symbol (*) denotes significant differences (P < 0.05) with non‐diabetic, symbol ($) denotes
significant differences (P < 0.05) with diabetic group. Abbreviations: ND, non‐diabetic; D, diabetic; ZnONPs + D, zinc oxide nanoparticle–treated diabetic
group; OD, optical density; TNF‐α, tumour necrosis factor‐α; VEGEF‐A, vascular endothelial growth factor‐A
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MMP‐9 contributes to mesangial matrix accumulation in the
diabetic kidney [33]. Therefore, increased degradation, as
well as decreased ECM protein synthesis could contribute to
the observed anti‐fibrotic effects of ZnONPs treatment in
DN disease.
Mitochondrial reactive oxygen species (ROS) production
such as superoxide anions, hydrogen peroxide and hydroxyl
radicals is found to be increased during hyperglycemia [39].
Excess ROS generation activates several signalling pathways
and transcription factors, including protein kinase C,
mitogen‐activated protein kinases and TGF‐β, which in turn
causes increased expression of ECM proteins and progres-
sion to renal fibrosis [5,39]. Thereby, restoration of the
antioxidant defence system by using exogenous anti‐oxida-
tive agents prevented ROS‐mediated diabetic kidney disease
[40]. In many diseases, including DN, the antioxidant
properties of Zn have been well documented [11,13]. In the
present study, ZnONPs treatment improved the renal anti-
oxidant defence mechanisms as indicated by the decrease in
MDA level and the increase in antioxidant enzymatic ac-
tivities, which are responsible for protection from oxidative
stress (i.e. SOD, CAT and GPx).
Abnormal angiogenesis has been identified as a signifi-
cant consequence during the development of DN [6].
Therefore, therapeutic options have been proposed to
prevent or delay the nephropathy process in diabetic patients
by targeting angiogenic factors such as VEGF‐A and
angiopoietins. The current study demonstrated an inhibitory
effect of ZnONP on the angiogenesis of nephropathic
diabetic rats, as shown by downregulation of the VEGF‐A
marker. The anti‐angiogenic effect of ZnONP has been
described in many reports [41,42]. Our findings are consis-
tent with these previous findings, showing the same impact
of nanoparticles by preventing the formation of new blood
vessels. The exact mechanism by which ZnONPs inhibit the
expression of VEGF‐A is not understood. However,
conformational changes in the structure of the VEGF‐A has
been proposed as a mechanism of nanoparticles anti‐
angiogenic effects [43].
The inflammation process is one of the significant driving
mechanisms that are involved in the development of DN.
TNF‐α is a proinflammatory cytokine that plays a pivotal role
in the development of microvascular diabetic complications,
including DN [44].Therapeutic strategies aiming to inhibit
TNF‐α production showed improvement of glomerular and
tubulointerstitial injury in patients with DN [44]. The anti‐in-
flammatory effects of ZnONPs have been described in mul-
tiple studies [17,45,46]. In a previous study, Min‐Ho Kim et al.
reported that ZnONPs exhibited an anti‐inflammatory effect
by downregulating the expression of interleukin (IL)‐1β, IL‐6,
and TNF‐α [45]. Consistent with this, our findings support a
potential anti‐inflammatory behaviour for ZnONPs in the
prevention of DN by inhibiting the expression of inflamma-
tory cytokines (TGF‐β1 and TNF‐α).
In conclusion, ZnONPs ameliorate the renal damage in
the experimental DN rat model through the improvement of
renal function, inhibition of renal fibrosis, oxidative stress,
inflammation, and abnormal angiogenesis and the ameliora-
tion of podocyte injury. All data are summarised in Supple-
ment 2. These findings may help in designing clinical
applications of ZnONPs for protection against the develop-
ment of DN.
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S u p p l e m e n t 1 Histograms representing serum alanine
aminotransferase and aspartate aminotransferase values after treating
diabetic rats with zinc oxide nanoparticles
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S u p p l e m e n t 2 Summary of all values in the study
Group
Non‐diabetic (ND) Diabetic (D) ZnONPs + D p valueD versus ZnONPs + DParameter
UAE rate mg/ml 0.157 ± 0.042 0.733 ± 0.058 0.2874 ± 0.059 <0.0001
Blood glucose mg/dl 113.7 ± 4.784 370.6 ± 23.7 194.7 ± 49.64 0.0012
BUN levels mg/dl 44.77 ± 1.12 128.4 ± 5.694 77.04 ± 18.76 0.0059
KWI 0.6336 ± 0.019 1.161 ± 0.037 0.8006 ± 0.134 0.0067
Renal tissue SOD activity (U/mg) 2.921 ± 0.1337 1.739 ± 0.360 2.907 ± 0.205 0.0095
Renal tissue GPx activity (U/mg) 12.59 ± 0.836 5.208 ± 0.526 8.5 ± 0.483 0.0021
Renal tissue CAT activity (U/mg) 5.544 ± 0.894 1.67 ± 0.314 6.611 ± 1.295 0.0019
Renal tissue malondialdehyde (MDA) level (µmol/mg) 0.0893 ± 0.029 0.553 ± 0.194 0.1417 ± 0.037 0.0232
relative TGF‐β1 mRNA expression level 1 ± 0 1.642 ± 0.221 0.697 ± 0.092 <0.0001
Relative VEGF‐A mRNA expression level 1 ± 0 1.883 ± 0.2546 0.3864 ± 0.1319 <0.0001
Relative MMP‐9 mRNA expression level 1 ± 0 0.275 ± 0.06 0.8205 ± 0.2396 0.0251
Relative fibronectin mRNA expression level 1 ± 0 1.858 ± 0.439 0.07833 ± 0.044 0.0003
Relative TNF‐α mRNA expression level 1 ± 0 1.624 ± 0.278 0.6654 ± 0.185 0.0025
Note: Each value is expressed as mean ± SEM.
Abbreviations: BUN, blood urea nitrogen; CAT, catalase; GP, glutathione peroxidase; KWI, Kidney weight index; SOD, superoxide dismutase; UAE, Urinary albumin excretion.
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